跳至主要内容
临床试验/NCT06511531
NCT06511531尚未招募不适用

Clinical Features and Possible Mechanisms in Patients With Sarcopenia in Parkinson's Disease

Central South University0 个研究点目标入组 200 人开始时间: 2024年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
200
主要终点
the SARC-F

研究概览

简要总结

Parkinson's Disease (PD) and sarcopenia are prevalent age-related syndromes, often occurring simultaneously within individuals. Sarcopenia is notably common among PD patients, with severe cases affecting approximately one in every five individuals with PD. Moreover, sarcopenia is closely linked to the accelerated progression of PD, diminished quality of life, heightened mortality risk, and increased susceptibility to falls and fractures. Therefore, early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration, potentially influencing PD outcomes. This review will delve into the relationship between sarcopenia and PD, methods for screening and testing sarcopenia, and potential avenues for further research and the development of strategies for risk reduction and treatment

详细描述

The onset of sarcopenia in PD may be intricately linked to both motor and non-motor symptoms. In terms of motor symptoms, sarcopenia exacerbates muscle weakness, impairs balance and gait, and may worsen symptoms like rigidity and bradykinesia in PD. Numerous studies have shown that sarcopenia is strongly associated with disease duration, Hoehn-Yahr staging, and Unified PD Rating Scale-III(UPDRSIII) scores. Regarding non-motor symptoms, sarcopenia contributes to increased fatigue due to muscle weakness, disrupts sleep patterns, exacerbates psychological distress including depression and anxiety, and may impact cognitive function. In addition, some studies supported that the incidence of falls, disability and death in PD with Sarcopenia were higher than those in PD without sarcopenia.

Nevertheless, other studies have reported controversial results. Some researchers believed that sarcopenia had no correlations with disease duration, HY, UPDRS-I/III, cognition and depression. However, most of the current studies are small cross-sectional studies that are not very convincing about the relationship between diseases. Thus, further studies with long-term follow up and large sample sizes are required to determine the causal direction of these relationships.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed as either ''definite'' or ''probable'' PD based on Chinese diagnostic criteria of Parkinson's disease (2016 version)

排除标准

  • Parkinson's syndrome or Parkinsonian superimposed syndrome due to encephalitis, cerebrovascular disease, poisoning, trauma, drugs or other factors

结局指标

主要结局

the SARC-F

时间窗: 12 months

The SARC-F is a simple screening tool for sarcopenia, consisting of five questions on strength, assistance in walking, rising from a chair, climbing stairs, and falls. Each question is scored from 0 to 2, with a total score of 4 or more indicating a risk of sarcopenia.

次要结局

  • Low Muscle Mass(12 months)
  • Poor Physical Performance(12 months)
  • Low Muscle Strength(12 months)

研究者

发起方
Central South University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Lixia Qin

Principal Investigator

Central South University

相似试验

Exploring Sarcopenia in Parkinson's Disease Patients... | 临床试验